Literature DB >> 27580246

IFN-γ Release Assay Result Is Associated with Disease Site and Death in Active Tuberculosis.

Sara C Auld1, Scott H Lee2, Eleanor S Click3, Roque Miramontes4, Cheryl L Day5, Neel R Gandhi6, Charles M Heilig2.   

Abstract

RATIONALE: The IFN-γ release assays and tuberculin skin tests are used to support the diagnosis of both latent and active tuberculosis. However, we previously demonstrated that a negative tuberculin test in active tuberculosis is associated with disseminated disease and death. It is unknown whether the same associations exist for IFN-γ release assays.
OBJECTIVES: To determine the association between these tests and site of tuberculosis and death among persons with active tuberculosis.
METHODS: We analyzed IFN-γ release assays and tuberculin test results for all persons with culture-confirmed tuberculosis reported to the U.S. National Tuberculosis Surveillance System from 2010 to 2014. We used logistic regression to calculate the association between these tests and site of disease and death.
MEASUREMENTS AND MAIN RESULTS: A total of 24,803 persons with culture-confirmed tuberculosis had either of these test results available for analysis. Persons with a positive tuberculin test had lower odds of disseminated disease (i.e., miliary or combined pulmonary and extrapulmonary disease), but there was no difference in the odds of disseminated disease with a positive IFN-γ release assay. However, persons who were positive to either of these tests had lower odds of death. An indeterminate IFN-γ release assay result was associated with greater odds of both disseminated disease and death.
CONCLUSIONS: Despite perceived equivalence in clinical practice, IFN-γ release assays and tuberculin test results have different associations with tuberculosis site, yet similar associations with the risk of death. Furthermore, an indeterminate IFN-γ release assay result in a person with active tuberculosis is not unimportant, and rather carries greater odds of disseminated disease and death. Prospective study may improve our understanding of the underlying mechanisms by which these tests are associated with disease localization and death.

Entities:  

Keywords:  Mycobacterium tuberculosis; public health surveillance; tuberculin test

Mesh:

Year:  2016        PMID: 27580246      PMCID: PMC5466186          DOI: 10.1513/AnnalsATS.201606-482OC

Source DB:  PubMed          Journal:  Ann Am Thorac Soc        ISSN: 2325-6621


  23 in total

1.  6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial.

Authors:  Taraz Samandari; Tefera B Agizew; Samba Nyirenda; Zegabriel Tedla; Thabisa Sibanda; Nong Shang; Barudi Mosimaneotsile; Oaitse I Motsamai; Lorna Bozeman; Margarett K Davis; Elizabeth A Talbot; Themba L Moeti; Howard J Moffat; Peter H Kilmarx; Kenneth G Castro; Charles D Wells
Journal:  Lancet       Date:  2011-04-12       Impact factor: 79.321

2.  Inadequate values from an interferon-gamma release assay for smear-negative tuberculosis in a high-burden setting.

Authors:  F Liu; F-J Du; H-Y Jia; L-P Pan; X Zhang; A-Y Xing; B-P Du; Q Sun; L-H Nie; H Li; R-M Liu; Y Ma; Z-D Zhang
Journal:  Int J Tuberc Lung Dis       Date:  2014-12       Impact factor: 2.373

3.  Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection - United States, 2010.

Authors:  Gerald H Mazurek; John Jereb; Andrew Vernon; Phillip LoBue; Stefan Goldberg; Kenneth Castro
Journal:  MMWR Recomm Rep       Date:  2010-06-25

Review 4.  The tuberculin skin test.

Authors:  R E Huebner; M F Schein; J B Bass
Journal:  Clin Infect Dis       Date:  1993-12       Impact factor: 9.079

5.  An indeterminate result of QuantiFERON-TB Gold In-Tube for miliary tuberculosis due to a high level of IFN-γ production.

Authors:  Sho Hangai; Akihide Yoshimi; Atsuko Hosoi; Keisuke Matsusaka; Motoshi Ichikawa; Masashi Fukayama; Mineo Kurokawa
Journal:  Int J Hematol       Date:  2014-01-31       Impact factor: 2.490

6.  Mortality before or during treatment among tuberculosis patients in North Carolina, 1993-2003.

Authors:  L T Nguyen; C D Hamilton; Q Xia; J E Stout
Journal:  Int J Tuberc Lung Dis       Date:  2011-02       Impact factor: 2.373

Review 7.  Specific immune-based diagnosis of tuberculosis.

Authors:  P Andersen; M E Munk; J M Pollock; T M Doherty
Journal:  Lancet       Date:  2000-09-23       Impact factor: 79.321

8.  An indeterminate QuantiFERON TB-2G response for miliary tuberculosis, due to severe pancytopenia.

Authors:  Yoshihiro Kobashi; Minoru Fukuda; Kouichiro Yoshida; Mikio Oka
Journal:  J Infect Chemother       Date:  2007-12-25       Impact factor: 2.211

9.  Histopathologic pattern analysis of human intracutaneous tuberculin reaction.

Authors:  Y Kuramoto; H Tagami
Journal:  Am J Dermatopathol       Date:  1989-08       Impact factor: 1.533

10.  Latent tuberculosis in HIV positive, diagnosed by the M. tuberculosis specific interferon-gamma test.

Authors:  Inger Brock; Morten Ruhwald; Bettina Lundgren; Henrik Westh; Lars R Mathiesen; Pernille Ravn
Journal:  Respir Res       Date:  2006-04-01
View more
  4 in total

1.  Delayed diagnosis of multiple systemic disseminated tuberculosis: A case report.

Authors:  Huan Li; Fang He; Cejun Zhong; Junyan Qu
Journal:  Medicine (Baltimore)       Date:  2022-02-18       Impact factor: 1.817

2.  Levels of TB-IGRA may help to differentiate between intestinal tuberculosis and Crohn's disease in patients with positive results.

Authors:  Yujie Zhao; Meilin Xu; Liang Chen; Zhanju Liu; Xiaomin Sun
Journal:  Therap Adv Gastroenterol       Date:  2020-05-18       Impact factor: 4.409

3.  Concurrent cavitary pulmonary tuberculosis and COVID-19 pneumonia with in vitro immune cell anergy.

Authors:  Maria Musso; Francesco Di Gennaro; Gina Gualano; Silvia Mosti; Carlotta Cerva; Saeid Najafi Fard; Raffaella Libertone; Virginia Di Bari; Massimo Cristofaro; Roberto Tonnarini; Concetta Castilletti; Delia Goletti; Fabrizio Palmieri
Journal:  Infection       Date:  2021-01-17       Impact factor: 3.553

4.  Relevance of QuantiFERON-TB Gold Plus and Heparin-Binding Hemagglutinin Interferon-γ Release Assays for Monitoring of Pulmonary Tuberculosis Clearance: A Multicentered Study.

Authors:  Carole Chedid; Eka Kokhreidze; Nestani Tukvadze; Sayera Banu; Mohammad Khaja Mafij Uddin; Samanta Biswas; Graciela Russomando; Chyntia Carolina Díaz Acosta; Rossana Arenas; Paulo Pr Ranaivomanana; Crisca Razafimahatratra; Perlinot Herindrainy; Julio Rakotonirina; Antso Hasina Raherinandrasana; Niaina Rakotosamimanana; Monzer Hamze; Mohamad Bachar Ismail; Rim Bayaa; Jean-Luc Berland; Flavio De Maio; Giovanni Delogu; Hubert Endtz; Florence Ader; Delia Goletti; Jonathan Hoffmann
Journal:  Front Immunol       Date:  2021-02-02       Impact factor: 8.786

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.